Inhibrx Biosciences (INBX) Assets Average (2024 - 2025)
Inhibrx Biosciences (INBX) reported Assets Average of $162.0 million for Q4 2025, down 19.68% year-over-year from $201.7 million in Q4 2024, and down 16.85% quarter-over-quarter from $194.8 million in Q3 2025.
Inhibrx Biosciences (INBX) Assets Average (2024 - 2025) Analysis & Trends
Inhibrx Biosciences (INBX) has 2 years of Assets Average data on file, last reported at $162.0 million in Q4 2025.
- Assets Average for Q4 2025 came in at $162.0 million, down 19.68% year-over-year; the trailing twelve-month figure through Dec 2025 was $162.0 million (down 19.68% YoY), and the FY2025 annual result was $163.6 million, down 33.03% from the prior year.
- Assets Average slipped to $162.0 million in Q4 2025 per INBX's latest filing, from $194.8 million in the prior quarter.
- Over five years, Assets Average peaked at $240.5 million in Q3 2024 and troughed at $162.0 million in Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Assets Avg. (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | 33.42 Mn |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | 795.91 Mn |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | 13.04 Mn |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | 1.72 Bn |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | 26.03 Mn |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | 40.89 Mn |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | 10.06 Mn |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 26.06 Bn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | 660.38 Mn |
| 10 | Inhibrx Biosciences | 186.16 Mn | 186.16 Mn | - | 161.97 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 161.97 Mn |
| Sep 30, 2025 | 194.79 Mn |
| Jun 30, 2025 | 227.38 Mn |
| Mar 31, 2025 | 211.70 Mn |
| Dec 31, 2024 | 201.66 Mn |
| Sep 30, 2024 | 240.49 Mn |